5.28 Combining Fludarabine and Rituximab With Escalating Doses of Lenalidomide in Untreated Chronic Lymphocytic Leukemia: The REVLIRIT CLL5 AGMT Phase 1/2 Study—Results from Clinical and Exploratory Analyses of Induction
Titel:
5.28 Combining Fludarabine and Rituximab With Escalating Doses of Lenalidomide in Untreated Chronic Lymphocytic Leukemia: The REVLIRIT CLL5 AGMT Phase 1/2 Study—Results from Clinical and Exploratory Analyses of Induction
Auteur:
Egle, A. Steurer, M. Gassner, F. Geisberger, R. Melchardt, T. Weiss, L. Fridrik, M. Thaler, J. Lang, A. Greil, R.